These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
413 related articles for article (PubMed ID: 6391662)
41. [Chemotherapy and immunomodulating treatment of patients with multiple myeloma]. Kraj M; Dmoszyńska A; Maj S; Kowalewski J; Rostkowska J; Pogłód R; Sokołowska B; Mendek-Czajkowska E; Kurowska M; Sokołowska U Acta Haematol Pol; 1991; 22(1):4-20. PubMed ID: 1823965 [TBL] [Abstract][Full Text] [Related]
42. Alternating combination chemotherapy does not delay development of refractoriness in myeloma. Osby E; Beksac M; Reizenstein P Anticancer Res; 1986; 6(5):1145-7. PubMed ID: 3800322 [TBL] [Abstract][Full Text] [Related]
43. [Treatment of multiple myeloma in stages I and II. Comparative study of an M-2 protocol and melphalan-prednisone]. Montalbán C; Zapatero A; Blanco L; Sevilla F; García Laraña J; Odriozola J Sangre (Barc); 1984; 29(6):993-9. PubMed ID: 6549486 [No Abstract] [Full Text] [Related]
44. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957 [TBL] [Abstract][Full Text] [Related]
45. [The influence of verapamil on platelet function in patients with multiple myeloma]. Sokołowska B; Dmoszyńska A; Walter-Croneck A; Wojtaszko M Pol Merkur Lekarski; 1997 Feb; 2(8):109-10. PubMed ID: 9538652 [TBL] [Abstract][Full Text] [Related]
46. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. Bladé J; San Miguel JF; Alcalá A; Maldonado J; Sanz MA; García-Conde J; Moro MJ; Alonso C; Besalduch J; Zubizarreta A J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503 [TBL] [Abstract][Full Text] [Related]
47. [Analysis of the results of treatment of multiple myeloma]. Snigurowicz J; Rostkowska J; Kraj M; Mariańska B Acta Haematol Pol; 1979 Oct; 10(4):227-35. PubMed ID: 539350 [TBL] [Abstract][Full Text] [Related]
48. [Therapeutic plasmapheresis in patients with multiple myeloma]. Mendek-Czajkowska E; Kraj M; Pogłód R; Rostkowska J; Maj S; Sabliński J Acta Haematol Pol; 1991; 22(1):31-41. PubMed ID: 1823964 [TBL] [Abstract][Full Text] [Related]
49. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study. Tribalto M; Amadori S; Cudillo L; Caravita T; Del Poeta G; Meloni G; Avvisati G; Petrucci MT; Pulsoni A; Leone G; Sica S; Martelli M; Tabilio A; Fioritoni G; Majolino I; Mandelli F Haematologica; 2000 Jan; 85(1):52-8. PubMed ID: 10629592 [TBL] [Abstract][Full Text] [Related]
50. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727 [TBL] [Abstract][Full Text] [Related]
51. Cyclophosphamide, doxorubicin, prednisone and vindesine combination chemotherapy in melphalan-resistant multiple myeloma. Van Dobbenburgh OA; Houwen B; Piersma H; Marrink J; Ockhuizen T; Halie MR; Nieweg HO Neth J Med; 1984; 27(2):25-30. PubMed ID: 6709108 [No Abstract] [Full Text] [Related]
52. Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112. Chou T; Tobinai K; Uike N; Asakawa T; Saito I; Fukuda H; Mizoroki F; Ando K; Iida S; Ueda R; Tsukasaki K; Hotta T; Jpn J Clin Oncol; 2011 Apr; 41(4):586-9. PubMed ID: 21247967 [TBL] [Abstract][Full Text] [Related]
53. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. Salmon SE; Tesh D; Crowley J; Saeed S; Finley P; Milder MS; Hutchins LF; Coltman CA; Bonnet JD; Cheson B J Clin Oncol; 1990 Sep; 8(9):1575-84. PubMed ID: 2131793 [TBL] [Abstract][Full Text] [Related]
54. Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol. Pileri A; Barbui T; Boccadoro M; Comotti B; Dammacco F; Gallamini A; Marmont F; Neretto G; Petrucci MT; Resegotti L Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():168-9. PubMed ID: 2713554 [No Abstract] [Full Text] [Related]
55. [Recent therapy for refractory myeloma]. Togawa A Rinsho Ketsueki; 1993 Apr; 34(4):450-4. PubMed ID: 8510332 [TBL] [Abstract][Full Text] [Related]
56. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727 [TBL] [Abstract][Full Text] [Related]
57. Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial. Scheithauer W; Cortelezzi A; Fritz E; Kührer I; Polli E; Baldini L; Ludwig H J Biol Response Mod; 1989 Apr; 8(2):109-15. PubMed ID: 2659740 [TBL] [Abstract][Full Text] [Related]
58. Refractory multiple myeloma treated with homoharringtonine: report of two cases. Yang X; Yang C; Shao K; Ye X; Meng H; Zhou Y; Qian W Ann Hematol; 2007 Dec; 86(12):919-21. PubMed ID: 17641891 [No Abstract] [Full Text] [Related]
59. Results and further perspectives of plasmocytoma chemotherapy. Sakalová A; Hrubisko M; Gazová S; Steruská M; Prümmerová J Neoplasma; 1986; 33(2):251-8. PubMed ID: 3520353 [TBL] [Abstract][Full Text] [Related]